<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01659281</url>
  </required_header>
  <id_info>
    <org_study_id>WRAIR-1327</org_study_id>
    <nct_id>NCT01659281</nct_id>
  </id_info>
  <brief_title>Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand</brief_title>
  <official_title>Efficacy of Artesunate-Mefloquine Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Trat Province, Thailand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armed Forces Research Institute of Medical Sciences, Thailand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Armed Forces Research Institute of Medical Sciences, Thailand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare artesunate-mefloquine combination therapy given
      for 2 and 3 days at the same total dose for the treatment of uncomplicated falciparum
      malaria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, open-label comparison of two versus three days
      artesunate-mefloquine treatment in patients with uncomplicated falciparum malaria. Primary
      endpoints will be 63-day parasitological cure rates in the 2 treatment groups. Secondary
      endpoints will be parasitological failure rates at each of the weekly follow-up visits to Day
      56, occurence of treatment-emergent adverse events on days 0, 1 and 2, mefloquine blood
      concentrations on days 7, 14 and 28, and in vitro drug sensitivity profiles for parasite
      isolates as measured by inhibitory concentrations. Genotyping of parasites for known markers
      of drug resistence will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of parasitological cure rate of directly observed antimalarial therapy</measure>
    <time_frame>63 days from initiation of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parasitological cure rates</measure>
    <time_frame>Weekly to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of treatment-emergent adverse events</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vitro drug sensitivity profile for individual parasite isolates</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mefloquine whole blood concentrations</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Plasmodium Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2-day oral treatment with: Artesunate 6mg/kg at 0 and 24 hours Mefloquine 25 mg/kg total dose split into 2 doses of 15 mg/kg at 0 hours and and 10 mg/kg given 6-24 hours later Primaquine 0.5 mg/kg single dose at 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 days oral treatment with: Artesunate 4 mg/kg/day for 3 days Mefloquine 8 mg/kg/day for 3 days Primaquine 0.5 mg/kg single dose at 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate</intervention_name>
    <description>6 mg/kg/day for 2 days (total dose 12 mg/kg)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate</intervention_name>
    <description>4 mg/kg/day for 3 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mefloquine</intervention_name>
    <description>15mg/kg at T=0 and 10 mg/kg 6-24 hours later</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mefloquine</intervention_name>
    <description>8 mg/kg daily for 3 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 5 to 70 years inclusive. If aged &lt; 18 years the subject must have a parent or
             guardian in attendance.

          2. Asexual stages of P. falciparum parasites in a thick or thin blood film with no other
             visible plasmodial species.

          3. Willing to give informed consent. Parents or guardians of children and adolescents
             must agree to give informed consent. Assent is necessary in addition to parental
             informed consent.

          4. Able to tolerate oral therapy.

          5. Willing to attend follow-up appointments and undergo study procedures.

        Exclusion Criteria:

          1. History of anti-malarial drug use within the past two weeks or mefloquine (MQ) use
             within 4 weeks.

          2. Bleeding tendency (by history or based on medical records).

          3. Severe/complicated malaria as determined by the investigator (coma or seizures,
             pulmonary edema, shock, renal failure, jaundice, severe anemia, spontaneous bleeding,
             hyperparasitemia (&gt;5% RBCs infected), or prostration).

          4. History of allergy to or intolerance of study medications.

          5. Mixed malaria infection by Giemsa stain.

          6. Any other condition that in the opinion of the study investigator warrants parenteral
             antimalarial treatment.

          7. Pregnant woman or nursing mother
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wichai - Satimai, M.D., D.T.M. &amp; H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bureau of Vector-Borne Disease, Department of Disease Control, Ministry of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark M. Fukuda, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Immunology and Medicine, AFRIMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vector Borne Diseases Control Units (VBDC, malaria clinics)</name>
      <address>
        <city>Borai, Khaosaming and Muang districts</city>
        <state>Trat</state>
        <zip>23000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>August 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2012</study_first_posted>
  <last_update_submitted>August 6, 2012</last_update_submitted>
  <last_update_submitted_qc>August 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Armed Forces Research Institute of Medical Sciences, Thailand</investigator_affiliation>
    <investigator_full_name>Douglas Walsh</investigator_full_name>
    <investigator_title>Dept Chief</investigator_title>
  </responsible_party>
  <keyword>Artesunate</keyword>
  <keyword>Mefloquine</keyword>
  <keyword>Plasmodium Falciparum</keyword>
  <keyword>Thailand</keyword>
  <keyword>Uncomplicated Plasmodium Falciparum malaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Mefloquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

